Best for Breast
As terrible as it is to hear, there’s a lot of money in cancer. Treatments and cures of all kinds are always being developed and worked on so that one day we can hopefully live in a world without these risks. This all comes at a hefty price tag, of course.
Greenwich LifeSciences just shared the poster for the GP2 Phase 2b clinical trial final efficacy presented on Wednesday at the 2020 San Antonio Breast Cancer Symposium.
According to Greenwich LifeSciences CEO Snehal Patel: “The poster presented at the SABCS is important because the Kaplan Meier survival curves and demographic data further validate our promising HER2 3+ phase IIb data and support our plan to commence a phase III trial in 2021.”
Investors loved the news and Greenwich shares had skyrocketed over 1900% during the day. Shares were halted multiple times throughout this meteoric rise though, making it hard for investors to enter and exit the trade.
Now, as the company prepares to enter a Phase 3 clinical trial to treat a similar population of moderate to severe breast cancer patients, it will be interesting to see what’s left in store for company shares and valuation.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.